Abstract:Abstract Helper CD4+ T cells are key players in the adaptive immune response that differentiate into different subpopulations. One of these subpopulations are T helper 17 (Th17) cells. In cancer, the role of Th17 cells is still controversial. The dual effect that Th17 cells seem to have in cancer can be explained by the great heterogeneity and/or plasticity of these cells. Two different subpopulations of Th17 cells have been reported: regulatory or “non-pathogenic” Th17 cells and effector or “pathogenic” Th17 cells. We currently know that this dual behavior depends on the cytokine microenvironment in which Th17 cells differentiate. However, the molecular basis of how, when, and why Th17 cells differentiate into effector or regulatory populations, as well as its in vivo relevance, are still poorly understood. Here we show that intrinsic expression of TMEM176B can determine the fate of Th17 cells. TMEM176b is a druggable immunoregulatory ion channel which function was first described by our team. We have found that in in vitro differentiated Th17 cells, Tmem176b is over-expressed in regulatory Th17 cells compared to effector Th17 cells, in agreement with its immunoregulatory properties. Furthermore, we found that Tmem176b influence Th17 polarity, since Th17 in vitro differentiation with IL-6+TGF-β from naïve Tmem176b−/− CD4+ T cells results in an enhanced IFN-γ production. Same results were obtained by pharmacological inhibition of TMEM176B in WT CD4+ T cells. Functional evaluation of these cells showed a decreased regulatory capacity compared to WT Th17 cells. Thus, WT Th17 cells inhibited CD8+ T cell proliferation whereas Tmem176b−/− Th17 cells showed poor inhibitory capacity. Supporting this effector-like phenotype, Tmem176b−/− Th17 cells have higher basal pAKT/AKT ratio compared to WT Th17 cells. Furthermore, Tmem176b−/− Th17 cells have a better metabolic fitness than WT Th17 cells, with higher glycolysis and oxidative phosphorylation. It was reported that the effector role of Th17 cells is dependent on the IL-1β production through ASC-NLRP3-caspase 8 activation. Here we show that Tmem176b−/− Th17 cells stimulated with ATP have a higher Caspase-8 activation compared to WT Th17 cells. All these results suggest that Tmem176b deficiency leads to an effector-like Th17 cell phenotype when cells are differentiated in a regulatory cytokine microenvironment. Moreover, co-culture of Tmem176b−/− Th17 cells with in vitro generated exhausted CD8+ T cells results in a reduction of the frequency of terminal exhausted CD8+ T cells and of mitochondrial reactive oxygen species production compared to co-culture with WT Th17 cells. Therefore, Tmem176b−/− Th17 may have enhanced anti-tumor properties compared to WT Th17 cells. In conclusion, we have identified a new intrinsic regulator of Th17 cells, TMEM176B, which may constitute a molecular target to pharmacologically modulate these cells. Citation Format: Sofia Russo, Mateo Malcuori, Mercedes Segovia, Marcelo Hill. Immune and metabolic control of Th17 cells by TMEM176B: Potential implication in cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1412.

BLOC1S1 control of vacuolar organelle fidelity modulates T 2 cell immunity and allergy susceptibility

The transcriptional repressor Bcl6 controls the stability of regulatory T cells by intrinsic and extrinsic pathways.

Glycogen synthase kinase 3 controls T-cell exhaustion by regulating NFAT activation

Mitochondrial Lon protease promotes CD4 + T cell activation by activating the cGAS-STING-TBK1 axis in systemic lupus erythematosus

03.17 Impaired mitophagy in tregs is involved in breakdown of self-tolerance and development of autoimmune responses

Steady-state, therapeutic, and helminth-induced IL-4 compromise protective CD8 T cell bystander activation

The Crohn Disease-associated ATG16L1 T300A polymorphism regulates inflammatory responses by modulating TLR- and NLR-mediated signaling

Noc4L-Mediated Ribosome Biogenesis Controls Activation of Regulatory and Conventional T Cells.

LKB1 isoform expression modulates T cell plasticity downstream of PKCθ and IL-6

Dysregulated TGF-β Signaling Leads to Cell-Intrinsic Changes in T cell Development that Promote Allergic Inflammation

Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction

Intrinsic STING Switches off Pathogenetic Programs of Th1 Cells to Inhibit Colitis

TPL-2 Regulates Macrophage Lipid Metabolism and M2 Differentiation to Control TH2-Mediated Immunopathology

Control of T reg cell homeostasis and immune equilibrium by Lkb1 in dendritic cells

Low-Dose IL-2 Induces Bcl2 Expression and Resistance to Apoptosis in CD4 Regulatory T Cells

CTLA-4 expression by B-1a B cells is essential for immune tolerance

BLT1 in dendritic cells promotes Th1/Th17 differentiation and its deficiency ameliorates TNBS-induced colitis.

Excessive nucleic acid R-loops induce mitochondria-dependent epithelial cell necroptosis and drive spontaneous intestinal inflammation

Suppression of Tumorigenicity 2 (st2) Signaling is Required for Regulatory T Cell Control of Graft-Vs. Host Disease

LKB1-PTEN axis controls Th1 and Th17 cell differentiation via regulating mTORC1

Abstract 1412: Immune and metabolic control of Th17 cells by TMEM176B: Potential implication in cancer immunotherapy